Search Results : Cancer

1954 interactions found:

Novel Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
vav guanine nucleotide exchange factor 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • NRAGE signals death through JNK
  • Regulation of actin dynamics for phagocytic cup formation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • CD28 dependent Vav1 pathway
  • G alpha (12/13) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • VEGFR2 mediated vascular permeability
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RHOA GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOG GTPase cycle
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Potential therapeutics for SARS
  • Azathioprine ADME
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
ret proto-oncogene
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • RAF/MAP kinase cascade
  • RET signaling
  • NPAS4 regulates expression of target genes
  • Formation of the nephric duct
  • Formation of the ureteric bud
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
  • Sorafenib
  • 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Vandetanib
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Fostamatinib
  • Amuvatinib
  • Selpercatinib
  • Pralsetinib
Diseases 1
Diseases 2
  • Congenital central hypoventilation syndrome (CCHS)
  • Hirschsprung disease (HD)
  • Thyroid cancer
  • Renal agenesis and Renal adysplasia
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
protein tyrosine phosphatase non-receptor type 22
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
  • Type I diabetes mellitus
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
T cell receptor associated transmembrane adaptor 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • PIP3 activates AKT signaling
  • Downstream TCR signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
SH2B adaptor protein 3
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Regulation of KIT signaling
  • Negative regulation of FLT3
  • Factors involved in megakaryocyte development and platelet production
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
  • Pazopanib
Diseases 1
Diseases 2
  • Type I diabetes mellitus
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
ADAM metallopeptidase domain 15
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Degradation of the extracellular matrix
  • Invadopodia formation
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Name 1
growth factor receptor bound protein 2
Name2
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Synthesis of PIPs at the plasma membrane
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
  • Fostamatinib
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
replication timing regulatory factor 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Nonhomologous End-Joining (NHEJ)
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
PBX homeobox interacting protein 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
trafficking from ER to golgi regulator
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • COPII-mediated vesicle transport
  • Signaling by ALK fusions and activated point mutants
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
  • Thyroid cancer
  • Non-small cell lung cancer
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
proteasome maturation protein
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Proteasome assembly
  • Proteasome assembly
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
  • Keratosis linearis with ichthyosis congenita and sclerosing keratoderma; KLICK syndrome
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
CD164 molecule
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Name 1
growth factor receptor bound protein 2
Name2
phosphoinositide-3-kinase adaptor protein 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
NKD inhibitor of Wnt signaling pathway 2
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
tripartite motif containing 27
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • SUMOylation of ubiquitinylation proteins
  • Regulation of PTEN stability and activity
  • Suppression of apoptosis
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
ABI family member 3
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
WD repeat and FYVE domain containing 3
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
Lck interacting transmembrane adaptor 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
suppressor of cytokine signaling 7
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
ras homolog family member U
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Interleukin-4 and Interleukin-13 signaling
  • RHOU GTPase cycle
  • RHOU GTPase cycle
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
vav guanine nucleotide exchange factor 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • NRAGE signals death through JNK
  • Regulation of actin dynamics for phagocytic cup formation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • CD28 dependent Vav1 pathway
  • G alpha (12/13) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • VEGFR2 mediated vascular permeability
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RHOA GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOG GTPase cycle
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Potential therapeutics for SARS
  • Azathioprine ADME
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
ret proto-oncogene
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • RAF/MAP kinase cascade
  • RET signaling
  • NPAS4 regulates expression of target genes
  • Formation of the nephric duct
  • Formation of the ureteric bud
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
  • Sorafenib
  • 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Vandetanib
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Fostamatinib
  • Amuvatinib
  • Selpercatinib
  • Pralsetinib
Diseases 1
Diseases 2
  • Congenital central hypoventilation syndrome (CCHS)
  • Hirschsprung disease (HD)
  • Thyroid cancer
  • Renal agenesis and Renal adysplasia
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
protein tyrosine phosphatase non-receptor type 22
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
  • Type I diabetes mellitus
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
T cell receptor associated transmembrane adaptor 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • PIP3 activates AKT signaling
  • Downstream TCR signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
SH2B adaptor protein 3
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Regulation of KIT signaling
  • Negative regulation of FLT3
  • Factors involved in megakaryocyte development and platelet production
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
  • Pazopanib
Diseases 1
Diseases 2
  • Type I diabetes mellitus
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
ADAM metallopeptidase domain 15
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Degradation of the extracellular matrix
  • Invadopodia formation
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Name 1
growth factor receptor bound protein 2
Name2
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Synthesis of PIPs at the plasma membrane
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
  • Fostamatinib
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
replication timing regulatory factor 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Nonhomologous End-Joining (NHEJ)
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
PBX homeobox interacting protein 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
trafficking from ER to golgi regulator
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • COPII-mediated vesicle transport
  • Signaling by ALK fusions and activated point mutants
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
  • Thyroid cancer
  • Non-small cell lung cancer
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
proteasome maturation protein
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Proteasome assembly
  • Proteasome assembly
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
  • Keratosis linearis with ichthyosis congenita and sclerosing keratoderma; KLICK syndrome
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
CD164 molecule
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Name 1
growth factor receptor bound protein 2
Name2
phosphoinositide-3-kinase adaptor protein 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
NKD inhibitor of Wnt signaling pathway 2
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
tripartite motif containing 27
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • SUMOylation of ubiquitinylation proteins
  • Regulation of PTEN stability and activity
  • Suppression of apoptosis
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
ABI family member 3
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
WD repeat and FYVE domain containing 3
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
Lck interacting transmembrane adaptor 1
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
suppressor of cytokine signaling 7
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
growth factor receptor bound protein 2
Name2
ras homolog family member U
Pathway 1
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
Pathway 2
  • Interleukin-4 and Interleukin-13 signaling
  • RHOU GTPase cycle
  • RHOU GTPase cycle
Drugs 1
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Drugs 2
Diseases 1
Diseases 2

Page 24 out of 98 pages

© Madhavi K. Ganapathiraju 2012-2025